Date: 2015-11-09
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Company: OncoMed Pharmaceuticals (USA - CA)
Product: navicixizumab - anti-DLL4/VEGF bispecific (OMP-305B83)
Action
mechanism: bispecific antibody. OncoMed’s anti-DLL4/VEGF bispecific targets both DLL4 on the Notch cancer stem cell pathway and the VEGF receptor. This antibody is intended to have both anti-cancer stem cell and anti-angiogenic activity. The bispecific antibody was discovered using OncoMed’s proprietary MAbTrap™ antibody display technology, which enables the rapid identification of monoclonal antibodies that bind targets with high affinity and specificity.
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On November 9, 2015, OncoMed Pharmaceuticals presented preclinical data related to preclinical characterization of safety and efficacy for anti-DLL4/VEGF bispecific (OMP-305B83). Preclinical studies of OncoMed's dual-targeting anti-DLL4/VEGF bispecific antibody in xenograft tumor models demonstrated superior anti-tumor activity compared to either anti-DLL4 and anti-VEGF antibodies alone. The combination of anti-DLL4 and anti-VEGF resulted in broad-spectrum activity in many different tumor types including breast, colon, ovarian and pancreatic tumors. In serial transplantation studies, the anti-DLL4/VEGF bispecific antibody showed a greater effect than anti-DLL4 alone in delaying tumor recurrence following the termination of treatment and reducing the frequency of cancer stem cells in the tumors. Researchers also observed that simultaneous inhibition of DLL4 and VEGF induced a down-regulation of vasculature-related genes and decreased vasculature density. The anti-DLL4/VEGF bispecific antibody showed an improved cardiac profile in cynomolgus monkeys compared to anti-DLL4 which may translate to an improved safety profile in the clinic. OncoMed is currently testing the anti-DLL4/VEGF bispecific in a Phase 1a clinical trial for patients with advanced refractory solid tumors. These data were presented by Wang-Ching Yen, Ph.D., of OncoMed in a poster titled: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency (Abstract #C134) on November 8, 2015.
Is
general: Yes
